Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / BASIC RESEARCH
Ellagic acid inhibited cervical cancer growth via blocking the AKT/mTOR/STAT3 pathway
1
Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
2
Department of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong, China
Submission date: 2020-08-03
Final revision date: 2020-08-25
Acceptance date: 2020-09-17
Online publication date: 2020-11-15
Publication date: 2026-08-28
Corresponding author
Jie Yu
Department of Gynecology The Affiliated Hospital of Qingdao University Qingdao, Shandong 266003, China
Department of Gynecology The Affiliated Hospital of Qingdao University Qingdao, Shandong 266003, China
Arch Med Sci 2026;22(4):2389-2403
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Ellagic acid (EA) is a kind of herb extract. However, the effects and mechanisms of EA in cervical cancer treatment are unclear.
Material and methods:
Our present work investigated the effects of EA on HeLa cervical cancer cell biological activities and relative mechanisms. Hela cells were divided into 5 groups as the NC group, Low group, Middle group, High group and 5-Fu group. MTT assay and cell apoptosis assay were performed to evaluate cell proliferation and apoptosis. Wound closure assay was used to assess the effect of EA on HeLa cell migration. We also assessed the anti-tumor effect of EA on a cervical tumor bearing BALB/c mouse model. Furthermore, western blotting and immunohistochemistry assay were performed to evaluate the effect of EA on the activation of AKT/mTOR/STAT3 in vitro and in vivo.
Results:
The cell experiments showed that EA had effects to inhibit Hela cell biological activities including cell apoptosis, migration and invasion dose-dependently and AKT, mTOR, and STAT3 phosphorylation expression levels were significantly depressed after EA supplementation in the in vitro study. In the in vivo study, EA significantly depressed tumor growth with cell apoptosis significantly increasing and the AKT/mTOR/STAT3 pathway was significantly down-regulated in tumor tissues.
Conclusions:
EA had anti-tumor effects on cervical cancer by depressing the AKT/mTOR/STAT3 pathway in in vitro and in vivo study.
Ellagic acid (EA) is a kind of herb extract. However, the effects and mechanisms of EA in cervical cancer treatment are unclear.
Material and methods:
Our present work investigated the effects of EA on HeLa cervical cancer cell biological activities and relative mechanisms. Hela cells were divided into 5 groups as the NC group, Low group, Middle group, High group and 5-Fu group. MTT assay and cell apoptosis assay were performed to evaluate cell proliferation and apoptosis. Wound closure assay was used to assess the effect of EA on HeLa cell migration. We also assessed the anti-tumor effect of EA on a cervical tumor bearing BALB/c mouse model. Furthermore, western blotting and immunohistochemistry assay were performed to evaluate the effect of EA on the activation of AKT/mTOR/STAT3 in vitro and in vivo.
Results:
The cell experiments showed that EA had effects to inhibit Hela cell biological activities including cell apoptosis, migration and invasion dose-dependently and AKT, mTOR, and STAT3 phosphorylation expression levels were significantly depressed after EA supplementation in the in vitro study. In the in vivo study, EA significantly depressed tumor growth with cell apoptosis significantly increasing and the AKT/mTOR/STAT3 pathway was significantly down-regulated in tumor tissues.
Conclusions:
EA had anti-tumor effects on cervical cancer by depressing the AKT/mTOR/STAT3 pathway in in vitro and in vivo study.
REFERENCES (30)
1.
Narayanan BA, Geoffroy O, Willingharm MC, et al. P53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in Ellagic acid treated cancer cells. Cancer Lett 1999; 136: 215-21.
2.
Qiu Z, Zhou B, Jin L, et al. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol 2013; 59: 428-37.
3.
Larrosa M, Gonzalez-Sarras A, Yanez-Gascon MJ, et al. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 2010; 21: 717-25.
4.
Nandi S, Vracko M, Bagchi MC. Anticancer activity of selected phenolic compounds: QSAR studies using ridge regression and neural networks. Chem Biol Drug Des 2007; 70: 424-36.
5.
Catherine RE, Nicholas M, George P. Antioxidant properties of phenolic compounds. Cell 1997; 2: 152-9.
6.
Hayeshi R, Mutingwende I, Mavengere W, et al. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem Toxicol 2007; 45: 286-95.
7.
Larrosa M, Tomas-Barberan FA, Espin JC, et al. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem 2006; 17: 611-25.
8.
Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, et al. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem 2006; 54: 8956-61.
9.
Thresiamma KC, Kuttan R. Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol 1996; 40: 363-6.
10.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
11.
Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J NatI Cancer Inst 2000; 92: 690-8.
12.
Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
13.
Kumar D, Basu S, Parija L, et al. Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed Pharmacother 2016; 81: 31-7.
14.
Chiarini F, Lonetti A, Teti G, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012; 3: 1615-28.
15.
He SQ, Gao M, Fu YF, et al. Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling. Int J Clin Exp Pathol 2015; 8: 5175-81.
16.
Einaggar AC, Saini U, Naidu S, et al. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. Cancer Biol Ther 2016; 17: 1107-15.
17.
Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16: 360-7.
18.
Malik A, Afaq S, Shahid M, et al. Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. Asian Pac J Trop Med 2011; 4: 550-5.
19.
Edderkaoui M, Odinokova I, Ohno I, et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol 2008; 14: 3672-80.
20.
Kumar D, Basu S, Panrija L, et al. Curcumin and ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed Pharmacother 2016; 81: 31-7.
21.
Choi IJ, Cha MS, Park ES, et al. The efficacy of concurrent cisplatin and 5- flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J Gynecol Oncol 2008; 19: 129-34.
22.
Ying C, Wang S, Lu Y, et al. Glucose fluctuation increased mesangial cell apoptosis related to AKT signal pathway. Arch Med Sci 2019; 15: 730-7.
23.
Garg G, Shah JP, Toy EP. Comparison of surgery or radiotherapy on complications and quality of life in patients with the stage IB and IIA uterine cervical cancer. Gynecol Oncol 2010; 116: 587.
24.
Shukla S, Bharti AC, Hussain S, et al. Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol 2009; 135: 1701-9.
25.
Oh PS, Lim KT. HeLa cells treated with phytoglycoprotein (150 kDa) were killed by activation of caspase 3 via inhibitory activities of NF-kappaB and AP- 1. J Biomed Sci 2007; 14: 223-32.
26.
Zhao S, Shao L, Wang Y, Meng Q, Yu J. Ketamine exhibits anti-gastric cancer activity via induction of apoptosis and attenuation of PI3K/Akt/mTOR. Arch Med Sci 2020; 16: 1140-9.
27.
Sakamoto KM, Grant S, Saleiro D, et al. Target-ing novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab 2015; 114: 397-402.
28.
Wu CH, Chen AZ, Yen GC. Protective effects of glycyrrhizic acid and 18-glycyrrhetinic acid against cisplatin-induced nephrotoxicity in BALB/c mice. J Agric Food Chem 2015; 63: 1200-9.
29.
Jia X, Yang W, Han J, et al. Effects of lentivi-rus mediated STAT3 silencing on human chron-ic myeloid leukemia cells and leukemia mice. Int J Clin Exp Med 2014; 7: 4031-7.
30.
Jordan NJ, Dutkowski CM, Barrow D, et al. Impact of dual mTORC1/2 mTOR ki-nase inhibitor AZD8055 on acquired endo-crine resistance in breast cancer in vitro. Breast Cancer Res 2014; 16: R12.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
